Association of Anticardiolipin Antibodies with Vascular Access Occlusion in Hemodialysis Patients: Cause or Effect?

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Nephron

• Publication date

  2000-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000045833PMID 11124593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anticardiolipin antibodies.

  1999cited by this paper
• Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome.

  1998cited by this paper
• Binding of anticardiolipin antibodies to protein C via β2‐glycoprotein I (β2‐GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system

  1998cited by this paper
• Activation of endothelial cells in thrombosis and vasculitis.

  1997cited by this paper
• [Thrombosis and apoptosis].

  1997cited by this paper
• Endothelial Cells as a Target for Antiphospholipid Antibodies: Role of Anti‐Beta 2 Glycoprotein I Antibodies

  1997cited by this paper
• Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome.

  1997cited by this paper
• Characteristics of the clinical findings in patients with idiopathic thrombocytopenic purpura who are positive for anti-phospholipid antibodies.

  1997cited by this paper
• Oxidized low‐density lipoprotein (Ox‐LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome (APS)

  1997cited by this paper
• Chronic relapsing thrombotic thrombocytopenic purpura and antiphospholipid antibodies: A report of two cases

  1997cited by this paper
• Lipoprotein glycation and its metabolic consequences.

  1997cited by this paper
• Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment.

  1997cited by this paper
• The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant.

  1996cited by this paper
• Emerging cross-regulatory roles of immunity and autoimmunity in atherosclerosis

  1996cited by this paper
• A prospective evaluation of atherosclerotic risk factors and hypercoagulability in young adults with premature lower extremity atherosclerosis.

  1996cited by this paper
• Antibodies against Phospholipids other than Cardiolipin: Potential Roles for Both Phospholipid and Protein

  1996cited by this paper
• Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein.

  1996cited by this paper
• Review : Histocompatibility genes in antiphospholipid antibody syndrome

  1996cited by this paper
• On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies.

  1995cited by this paper
• Anti β2 glycoprotein I antibodies: detection and association with thrombosis

  1995cited by this paper
• Anti beta 2 glycoprotein I antibodies: detection and association with thrombosis.

  1995cited by this paper
• T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein.

  1995cited by this paper
• Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice.

  1994cited by this paper
• A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) Study.

  1994cited by this paper
• Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL.

  1994cited by this paper
• Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies.

  1994cited by this paper
• Antiphospholipid Antibodies in Vascular Surgery Patients A Cross‐Sectional Study

  1994cited by this paper
• Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus.

  1993cited by this paper
• Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?

  1993cited by this paper
• Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity.

  1993cited by this paper
• Anticardiolipin antibodies in patients on regular hemodialysis: an epiphenomenon?

  1993cited by this paper
• Coagulation Assays for the Lupus Anticoagulant: Review and Critique of Current Methodology

  1992cited by this paper
• Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H).

  1992cited by this paper
• Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor.

  1992cited by this paper
• Induction of T-cell activation by oxidized low density lipoprotein.

  1992cited by this paper
• A Phospholipid-β2-Glycoprotein I Complex Is an Antigen for Anticardiolipin Antibodies Occurring in Autoimmune Disease But Not with Infection

  1992cited by this paper
• The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta.

  1992cited by this paper
• Neuropathologic findings in multi-infarct dementia associated with anticardiolipin antibody. Evidence for endothelial injury as the primary event.

  1992cited by this paper
• Association of anti-β2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus☆

  1992cited by this paper
• Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes?

  1992cited by this paper
• Guidelines for Testing and Revised Criteria for Lupus Anticoagulants

  1991cited by this paper
• Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease.

  1991cited by this paper
• Raised concentrations of antibodies to cardiolipin in patients receiving dialysis.

  1990cited by this paper
• The mosaic of autoimmunity.

  1989cited by this paper
• THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS DESPITE CIRCULATING ANTICOAGULANTS.

  1963cited by this paper
• A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus

  1952cited by this paper

• Antiphospholipid Antibodies Associated with Native Arteriovenous Fistula Complications in Hemodialysis Patients: A Comprehensive Review of the Literature

  2024cites this paper
• Long-term prognosis of vascular access in hemodialysis patients with systemic lupus erythematosus: a retrospective cohort study

  2020cites this paper
• Long-term Prognosis of Vascular Access in Haemodialysis Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study

  2020cites this paper
• Antiphospholipid antibodies in end‐stage renal disease: A systematic review and meta‐analysis

  2020cites this paper
• Systemic lupus erythematosus diagnosis impacts clinical outcomes of arteriovenous fistulas in comparison to other end-stage renal disease etiologies

  2020cites this paper
• Renal Function Affects Prognostic Role of Antiphosphatidylserine Antibodies for Acute Ischemic Stroke Patients

  2019cites this paper
• Renal Involvement in Antiphospholipid Syndrome

  2018cites this paper
• Central retinal vein occlusion in a patient on hemodialysis secondary to antiphospholipid syndrome: Case report.

  2017cites this paper
• Kidney disease in primary anti-phospholipid antibody syndrome

  2017cites this paper
• Kidney disease in primary anti-phospholipid antibody syndrome.

  2016cites this paper
• Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort study.

  2016cites this paper
• Renal involvement in antiphospholipid syndrome

  2014cites this paper
• The Kidney in Antiphospholipid Syndrome

  2012cites this paper
• Antiphospholipid Antibodies and Renal Involvement

  2009cites this paper
• Renal Involvement in the Antiphospholipid Syndrome (APS)—APS Nephropathy

  2009cites this paper
• Anticardiolipin antibodies in hemodialysis patients with hepatitis C and their role in fistula failure.

  2009cites this paper
• Prognostic Factors Influencing the Patency of Hemodialysis Vascular Access: Literature Review and Novel Therapeutic Modality by Far Infrared Therapy

  2009cites this paper
• REVIEWARTICLES Recent developments in the perioperative management of adult patients with chronic kidney disease

  2008cites this paper
• Recent developments in the perioperative management of adult patients with chronic kidney disease.

  2008cites this paper
• Risk of vascular access thrombosis in patients with systemic lupus erythematosus on hemodialysis.

  2007cites this paper
• Risk of Vascular access Thrombosis in Patients with Systemic Lupus Erythematosus on Hemodialysis

  2007cites this paper
• Kidney disease in antiphospholipid syndrome.

  2006cites this paper
• Anticardiolipin antibodies and vascular access thrombosis in Taiwanese haemodialysis patients with chronic hepatitis C: a retrospective study

  2006cites this paper
• HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: Vascular Access Thrombosis Prophylaxis

  2006cites this paper
• Antiphospholipid syndrome and the kidneys.

  2006cites this paper
• Effect of 1-Year Oral α-Tocopherol Administration on Anticardiolipin Antibodies in Hemodialysis Patients

  2005influential citation
• Anticardiolipin antibody and Taiwanese chronic haemodialysis patients with recurrent vascular access thrombosis

  2005cites this paper
• The Relationship Between Anticardiolipin Antibodies and Vascular Access Occlusion in Patients on Hemodialysis

  2005cites this paper
• IgM-Anticardiolipin Antibody and Vascular Access Thrombosis in Chronic Hemodialysis Patients

  2005cites this paper
• Medical factors affecting patency of arteriovenous access.

  2004cites this paper
• Efficacy of reteplase in poorly functioning hemodialysis catheters.

  2004cites this paper
• Immune mechanisms in atherosclerotic vascular disease

  2002cites this paper
• "Black swan in the kidney": renal involvement in the antiphospholipid antibody syndrome.

  2002cites this paper
• Vascular Access Thrombosis Is Not Related to Presence of Antiphospholipid Antibodies in Patients on Chronic Hemodialysis

  2002cites this paper
• World Journal of Nephrology

  year unknowncites this paper